Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com

Articles

Frontline Osimertinib Approved in Europe for EGFR-mutant NSCLC

June 11th 2018

The European Commission has approved osimertinib (Tagrisso) as a frontline treatment for patients with EGFR-mutant locally-advanced or metastatic non–small cell lung cancer.

ASCO Studies Refine CAR T Cell Use

June 7th 2018

Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of CAR T-cell therapies, with a focus on predicting adverse events and optimizing efficacy.

Nivolumab Plus Low-Dose Ipilimumab Shows Durable Responses for PD-L1-Negative, TMB-High NSCLC

June 6th 2018

The combination of nivolumab and low-dose ipilimumab reduced the risk of progression or death by 52% compared with standard platinum doublet chemotherapy for patients with metastatic PD-L1–negative, tumor mutation burden-high non–small cell lung cancer.

Frontline Atezolizumab Regimen Improves Survival for NSCLC

June 5th 2018

The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.

Liso-Cel Shows Durable CRs for High-Risk DLBCL

June 4th 2018

Lisocabtagene maraleucel (JCAR017; liso-cel) demonstrated a durable complete remission rate of 46% at 6 months for patients with high-risk diffuse large B-cell lymphoma.

Rituximab/Lenalidomide Potential Frontline Therapy for Follicular Lymphoma

June 4th 2018

Similar efficacy with the combination of rituximab and lenalidomide coupled with a better safety profile compared with rituximab plus chemotherapy may make the chemo-free regimen a new frontline option for patients with previously untreated follicular lymphoma.

Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL

June 4th 2018

The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.

LOXO-292 Shows Impressive Response Rates for RET-Positive Tumors

June 2nd 2018

The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.

bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

June 2nd 2018

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma

June 2nd 2018

The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.

FDA Accepts Cabozantinib Application for Advanced HCC

May 30th 2018

The FDA has accepted a supplemental new drug application for cabozantinib as a treatment for patients with previously-treated advanced hepatocellular carcinoma.

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma

May 29th 2018

Two separate early-phase clinical trials exploring daratumumab in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer were terminated following a planned interim analysis.

FDA Delays Decision on Lenvatinib for HCC

May 25th 2018

The FDA has extended the review period for lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma. The new action date for the supplemental new drug application is August 24, 2018.

FDA Approves New Abiraterone Acetate Formulation for mCRPC

May 24th 2018

The FDA has approved a new formulation of abiraterone acetate in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer.

Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

May 22nd 2018

IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, which is nearly double the historical expectations for patients with the disease.

FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma

May 19th 2018

The FDA has issued a drug safety notification warning against the use of frontline single-agent immune checkpoint inhibition for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer

May 17th 2018

A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.

FDA Approves Frontline Daratumumab/VMP Combo for Multiple Myeloma

May 8th 2018

The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Regorafenib HCC Benefits Consistent in Additional Analyses

April 30th 2018

Second-line regorafenib (Stivarga) continued to show antitumor activity regardless of prior dose or time to progression on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma.

FDA Approves Fostamatinib for Chronic ITP

April 18th 2018

The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.